NASDAQ · TLSI
TriSalus Life Sciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TLSI: Nov 10, 2026
TriSalus Life Sciences, Inc. Common Stock is expected to report earnings on 11/10/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.96.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Dec 2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Mar 2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Jun 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · MarketBeat- Zacks · Oct 29, 9:30 AM EDTVerano Holdings Corp. (VRNO) Reports Q3 Loss, Lags Revenue EstimatesVerano Holdings Corp. (VRNO) delivered earnings and revenue surprises of +50.00% and -1.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Sep 25, 10:53 AM EDTWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) – Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across oncology, metabolic diseases, immunology and rare diseases.
- RTTNews · Sep 22, 10:54 PM EDTTriSalus Gets FDA Clearance For TriNav Advance For Liver Embolization; Overnight Stock Up 17%(RTTNews) – TriSalus Life Sciences, Inc. (TLSI), an oncology-focused medical technology company, said the U.S. Food and Drug Administration has granted 510(k) clearance to TriNav Advance, expanding its Pressure-Enabled Drug Delivery, or PEDD portfolio for liver embolization proce
- Fintel · Sep 9, 3:04 PM EDTHC Wainwright & Co. initiates coverage of TriSalus Life Sciences with a Buy ratingFintel reports that on September 9, 2026, HC Wainwright & Co. initiated coverage of TriSalus Life Sciences (NASDAQGM:TLSI) with a Buy recommendation.Prior to this rating action, the stock closed at $4.73 on September 8, 2026. This close represents a price change of -8.51% ove
- MarketBeat · Aug 18, 12:01 AM EDTTriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth ConferenceTriSalus Life Sciences (NASDAQ:TLSI) outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity’s Global Growth Conference, with management emphasizing the company’s pressure-enabled delivery technology for solid-tumor treatments.
- MarketBeat · Aug 7, 1:04 PM EDTTriSalus Life Sciences Q2 Earnings Call HighlightsTriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reiterated its full-year 2026 revenue outlook of $54 million to
- Zacks · Jun 30, 7:59 AM EDTQuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- The Motley Fool · May 14, 3:19 PM EDTTriSalus (TLSI) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · May 13, 11:23 AM EDTTriSalus Reports $1.5 Mln Net Income In Q1, Stock Tanks By 45%(RTTNews) – TriSalus Life Sciences Inc. (TLSI), an oncology company, on Wednesday reported its first-quarter results and provided various business updates.
- MarketBeat · May 12, 10:06 PM EDTTriSalus Life Sciences Q1 Earnings Call HighlightsTriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device. President and Chief
- Zacks · May 12, 5:15 PM EDTTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesTriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of +12.50% and -15.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 7:05 PM EDTVAREX IMAGING (VREX) Q2 Earnings and Revenues Miss EstimatesVAREX IMAGING (VREX) delivered earnings and revenue surprises of -4.55% and -0.55%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for TriSalus Life Sciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.